严重急性呼吸综合征冠状病毒2型野生型毒株与德尔塔（B.1.617.2）变异株之间疫苗接种的保护效果及临床特征比较。
A comparison of the protective effect of vaccination and clinical features between the SARS-CoV-2 wild-type strain and Delta (B.1.617.2) variant.
作者信息
Li Yanzi, Wang Zhi, Liu Junhui, Han Jianfeng, Yang Lin
机构信息
Department of Medical Administration, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Department of Infectious surgery, Xi'an 8 Hospital, Xi'an, China.
出版信息
Arch Med Sci. 2022 Nov 7;18(6):1678-1682. doi: 10.5114/aoms/155114. eCollection 2022.
Abstract
INTRODUCTION
This study aimed to investigate the clinical features and vaccine effectiveness of patients with the SARS-CoV-2 wild-type strain and the Delta variant.
METHODS
We retrospectively evaluated patients with the SARS-CoV-2 wild-type strain and the Delta variant.
RESULTS
The Delta-variant group showed a higher infection rate in minors, who had higher incidence of anosmia or dysgeusia and shorter incubation period. Unvaccinated patients had a 15.59-fold higher risk of severe classification than vaccinated patients. The viral clearance time was significantly shorter in the Delta-variant group.
CONCLUSIONS
The Delta-variant group show higher transmissibility, and vaccination reduces the incidence of severe classification and promotes viral clearance.
摘要
引言
本研究旨在调查感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）野生型毒株和德尔塔变异株患者的临床特征及疫苗有效性。
方法
我们对感染SARS-CoV-2野生型毒株和德尔塔变异株的患者进行了回顾性评估。
结果
德尔塔变异株组在未成年人中的感染率更高，这些未成年人嗅觉丧失或味觉障碍的发生率更高，潜伏期更短。未接种疫苗的患者出现严重分级的风险比接种疫苗的患者高15.59倍。德尔塔变异株组的病毒清除时间明显更短。
结论
德尔塔变异株组显示出更高的传播性，接种疫苗可降低严重分级的发生率并促进病毒清除。
相似文献
1
A comparison of the protective effect of vaccination and clinical features between the SARS-CoV-2 wild-type strain and Delta (B.1.617.2) variant.严重急性呼吸综合征冠状病毒2型野生型毒株与德尔塔（B.1.617.2）变异株之间疫苗接种的保护效果及临床特征比较。
Arch Med Sci. 2022 Nov 7;18(6):1678-1682. doi: 10.5114/aoms/155114. eCollection 2022.
2
COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.印度的新冠疫情动态、严重急性呼吸综合征冠状病毒2（SARS-CoV-2）德尔塔变异株及其对疫苗接种的影响
medRxiv. 2021 Nov 22:2021.06.21.21259268. doi: 10.1101/2021.06.21.21259268.
3
Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study.接种疫苗状态下感染 SARS-CoV-2 德尔塔变异株后儿童多系统炎症综合征的发生率和临床表型：一项丹麦全国前瞻性队列研究。
Lancet Child Adolesc Health. 2022 Jul;6(7):459-465. doi: 10.1016/S2352-4642(22)00100-6. Epub 2022 May 6.
4
Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants.阿尔法（B.1.1.7）和德尔塔（B.1.617.2）变异株之间的传播差异。
Microbiol Spectr. 2022 Apr 27;10(2):e0000822. doi: 10.1128/spectrum.00008-22. Epub 2022 Apr 12.
5
SARS-CoV-2 Delta Variant in Jingmen City, Hubei Province, China, 2021: Children Susceptible and Vaccination Breakthrough Infection.2021年中国湖北省荆门市的严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）德尔塔变异株：儿童易感及疫苗突破性感染
Front Microbiol. 2022 Apr 13;13:856757. doi: 10.3389/fmicb.2022.856757. eCollection 2022.
6
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.2021 年 7 月 15 日至 9 月 23 日和 2021 年 12 月 21 日至 2022 年 1 月 27 日期间，加利福尼亚州一家医院因实验室确诊的 SARS-CoV-2 感染住院的成年人的临床特征和结局，期间 B.1.617.2（德尔塔）和 B.1.1.529（奥密克戎）变异株占主导地位。
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2.
7
Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China.中国江苏 B.1.617.2（Delta）变异株感染者中新冠灭活疫苗对重症的保护效果。
Int J Infect Dis. 2022 Mar;116:204-209. doi: 10.1016/j.ijid.2022.01.030. Epub 2022 Jan 19.
8
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2（Delta）变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络，2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
9
Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection.疫苗接种对感染 SARS-CoV-2 德尔塔变异株（B.1.617.1）的住院患者症状的影响。
Clin Microbiol Infect. 2022 Dec;28(12):1629-1635. doi: 10.1016/j.cmi.2022.06.019. Epub 2022 Jun 30.
10
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.COVID-19 病例和住院情况按 COVID-19 疫苗接种状况和既往 COVID-19 诊断情况划分-加利福尼亚州和纽约州，2021 年 5 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131. doi: 10.15585/mmwr.mm7104e1.
本文引用的文献
1
Clinical Features of Adult COVID-19 Patients without Risk Factors before and after the Nationwide SARS-CoV-2 B.1.617.2 (Delta)-variant Outbreak in Korea: Experience from Gyeongsangnam-do.韩国全国范围内 SARS-CoV-2 B.1.617.2（德尔塔）变异株流行前后无危险因素的成年 COVID-19 患者的临床特征：来自庆尚南道的经验
J Korean Med Sci. 2021 Dec 20;36(49):e341. doi: 10.3346/jkms.2021.36.e341.
2
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.接种疫苗后对关注的 Delta（B.1.617.2）SARS-CoV-2 变异株的中和作用降低。
PLoS Pathog. 2021 Dec 2;17(12):e1010022. doi: 10.1371/journal.ppat.1010022. eCollection 2021 Dec.
3
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.英国未接种和接种疫苗人群中 SARS-CoV-2 德尔塔（B.1.617.2）变异株的社区传播和病毒载量动力学：一项前瞻性、纵向、队列研究。
Lancet Infect Dis. 2022 Feb;22(2):183-195. doi: 10.1016/S1473-3099(21)00648-4. Epub 2021 Oct 29.
4
Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant.SARS-CoV-2 Delta 变异株刺突蛋白介导的膜融合与免疫逃逸。
Science. 2021 Dec 10;374(6573):1353-1360. doi: 10.1126/science.abl9463. Epub 2021 Oct 26.
5
A high attack rate of 90% of SARS-CoV-2 Delta variant infections in crew personnel on a single navy ship.一艘海军舰艇上的船员感染新冠病毒德尔塔变异毒株的攻击率高达90%。
J Travel Med. 2021 Dec 29;28(8). doi: 10.1093/jtm/taab168.
6
Interpretation of the Protocol for Prevention and Control of COVID-19 in China (Edition 8).《新型冠状病毒肺炎防控方案（第八版）》解读
China CDC Wkly. 2021 Jun 18;3(25):527-530. doi: 10.46234/ccdcw2021.138.
7
Potential Implications of SARS-CoV-2 Delta Variant Surges for Rural Areas and Hospitals.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）德尔塔变异株激增对农村地区和医院的潜在影响
JAMA. 2021 Sep 21;326(11):1003-1004. doi: 10.1001/jama.2021.13941.
8
Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time.跳上移动的火车：实时追踪 SARS-CoV-2 的进化。
J Pediatric Infect Dis Soc. 2021 Dec 24;10(Supplement_4):S96-S105. doi: 10.1093/jpids/piab051.
9
Simultaneously complete but not partial taste and smell losses were associated with SARS-CoV-2 infection.同时完全丧失味觉和嗅觉与 SARS-CoV-2 感染有关。
Int J Infect Dis. 2021 May;106:329-337. doi: 10.1016/j.ijid.2021.03.083. Epub 2021 Apr 2.
10
Smell and taste dysfunction in patients with SARS-CoV-2 infection: A review of epidemiology, pathogenesis, prognosis, and treatment options.新型冠状病毒感染患者的嗅觉和味觉障碍：流行病学、发病机制、预后和治疗选择的综述。
Asian Pac J Allergy Immunol. 2020 Jun;38(2):69-77. doi: 10.12932/AP-030520-0826.
Zotero 插件